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LETTERS TO THE EDITOR 
Therapeutic Approach to Microvascular 
Angina (Syndrome X) 
I read with interest the study by Kaski et al. (1) on the use of enalapril 
in syndrome X. The therapeutic approach to this condition continues 
to focus on vasodilator agents despite previous reports of limited 
efficacy (2). Metabolic studies (3) have provided evidence of systemic 
insulin resistance inpatients with syndrome X. Myocardial metabolism 
in animal models of insulin resistance is characterized by increased 
cellular oxidation of fatty acids and markedly impaired oxidative 
glucose metabolism (4). This pattern of myocardial energy metabolism 
has also been demonstrated in patients with syndrome X (5) and 
suggests an alternative therapeutic approach to the condition. Inhibi- 
tion of fatty acid oxidation with carnitine palmitoyl transferase inhib- 
itors normalizes myocardial carbohydrate and fatty acid metabolism in
animal models of insulin resistance (4). Furthermore, carnitine palmi- 
toyl transferase inhibitors are nontoxic in vivo and have undergone 
trials as hypoglycemic agents in humans (6). 
Carnitine palmitoyl transferase inhibitors will be beneficial in 
syndrome X if the clinical manifestations of the condition result from 
the abnormal myocardial metabolism associated with insulin resis- 
tance. Certainly, exertional muscle pain is a recognized feature of 
metabolic myopathies. In addition, the occurrence of apparent isch- 
emic electrocardiographic changes is well documented in intramyocar- 
dial metabolic disturbances (7). The generalized abnormalities of 
vascular smooth muscle function characteristic of syndrome X have 
been demonstrated in both insulin-resistant and insulin-deficient states 
in humans (8). Both of these conditions are associated with increased 
cellular oxidation of fatty acids and impaired oxidative glucose metab- 
olism. Experimental studies (9) indicate that normal cellular glucose 
oxidation may be important for endothelium-dependent vascular 
smooth muscle relaxation. Hence, it is at least conceivable that the 
clinical manifestations of syndrome X result from the deranged ener~' 
metabolism associated with insulin resistance and could, therefore, be 
altered by carnitine palmitoyl transferase inhibitors. On the basis of 
the available vidence a trial of metabolic therapy in syndrome X 
appears to be justified. 
JOHN P. SEERY, MRCP 
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Reply 
I am grateful to Seery for his interesting comments. I share Seery's 
concern that the therapeutic approach to the so-called cardiac syn- 
drome X has focused mainly on antianginal gents, whether vasodila- 
tots or otherwise. However, there are reasons for this. An ischemic 
origin for syndrome X has been postulated in view of the anginal 
character of the chest pain, ST segment depression on exercise testing 
and findings of "objective" evidence for myocardial ischemia and 
reduced coronary blood flow reserve in some patients (1). Studies by 
Cannon et al. (2) further confirmed that patients with angina and 
normal coronary arteriographic findings had transient myocardial 
ischemia, as assessed by transmyocardial l ctate measurements and 
radionuclide ventriculography. In the absence of epicardial narrow- 
ings, prearteriolar microvascular dysfunction was postulated as the 
mechanism responsible for ischemia in this condition ("microvascular 
angina") (2). Recently, both microvascular endothelial dysfunction 
and ischemia were documented by Egashira et al. (3) in patients with 
syndrome X. However, despite evidence of myocardial ischemia in 
some patients, controversy exists as to the true nature of syndrome X. 
Indeed, abnormal coronary blood flow reserve and myocardial isch- 
emia can be objectively demonstrated in only a minority of patients 
with angina and normal coronary arteries (4). Other hypotheses have 
therefore been postulated; among these are abnormal pain perception, 
increased sympathetic activity and metabolic abnormalities. Studies 
have now focused on these mechanisms, and it has been shown (5) thal 
imipramine, a drug that has been used successfully in the managemen! 
of chronic pain syndromes, improved the symptoms of patients with 
chest pain and normal coronary arteriographic results. We recent b 
observed (6) that patients with syndrome X have impaired autonomic: 
function on the basis of reduced heart rate variability. Relevant o this 
observation, and to the effects of enalapril n patients with syndrome 
(7), is the fact that angiotensin II facilitates ympathetic nerve influ-- 
ences in the heart. Treatment with angiotensin-converting e zyme 
inhibitors is known to attenuate sympathetically mediated coronary 
vasoconstriction (7), and this could explain the beneficial effects o1! 
enalapril in our patients with syndrome X and microvascular ngina. 
Increased sympathetic drive is certainly an attractive pathogenetic 
hypothesis in the setting of angina with normal findings on the 
coronary arteriogram. Interaction between the central and sympathetic 
nervous systems may influence pain perception (4), and increased 
sympathetic drive is present in patients with insulin resistance, recently 
described in association with syndrome X (8). 
I agree with Seery that carnitine palmitoyl transferase inhibitors 
could be beneficial in patients with syndrome X for the reasons 
expressed in his letter. However, it would be erroneous to assume, a's 
Seery appears to do, that cardiac syndrome X is caused by abnormal 
cardiac metabolism due to insulin resistance, and, therefore, that 
interventions aimed at improving this metabolic abnormality will be 
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